Cytomegalovirus infections following chemotherapies of the newer generation.
Junghanss
Christian
C
Division of Hematology and Oncology, Department of Internal Medicine, University of Rostock, Rostock, Germany. christian.junghanss@med.uni-rostock.de
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000145:classification; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000209:etiology*; D004279:DNA, Viral / Q000097:blood; D004198:Disease Susceptibility; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced*; D014766:Viremia / Q000209:etiology; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D004279:DNA, Viral; D000074323:Alemtuzumab